keyword
MENU ▼
Read by QxMD icon Read
search

biomarkers bladder cancer

keyword
https://www.readbyqxmd.com/read/28214283/prognostic-role-of-n-cadherin-expression-in-patients-with-non-muscle-invasive-bladder-cancer
#1
Mohammad Abufaraj, Shahrokh F Shariat, Andrea Haitel, Marco Moschini, Beat Foerster, Piotr Chłosta, Kilian Gust, Marek Babjuk, Alberto Briganti, Pierre I Karakiewicz, Walter Albrecht
PURPOSE: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy. PATIENTS AND METHODS: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected...
February 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28212556/urinary-cell-microrna-based-prognostic-classifier-for-non-muscle-invasive-bladder-cancer
#2
Mercedes Ingelmo-Torres, Juan José Lozano, Laura Izquierdo, Albert Carrion, Meritxell Costa, Lidia Gómez, María José Ribal, Antonio Alcaraz, Lourdes Mengual
Current prognostic tools for non-muscle invasive bladder cancer (NMIBC) do not have enough discriminative capacity to predict the risk of tumour progression. This study aimed to identify urinary cell microRNAs that may be useful as non-invasive predictive biomarkers of tumour progression in NMIBC patients. To this end, 210 urine samples from NMIBC patients were included in the study. RNA was extracted from urinary cells and expression of 8 microRNAs, previously described by our group, was analysed by quantitative PCR...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28209906/first-evaluation-of-pet-based-human-biodistribution-and-dosimetry-of-18-f-faza-a-tracer-for-imaging-tumor-hypoxia
#3
Savi Annarita, Elena Incerti, Federico Fallanca, Valentino Bettinardi, Francesca Rossetti, Cristina Monterisi, Antonia Compierchio, Giampiero Negri, Piero Zannini, Luigi Gianolli, Maria Picchio
Fluorine-18 labelled fluoroazomycinarabinoside ((18)F-FAZA) is a positron emission tomography (PET) biomarker for non-invasive identification of regional tumor hypoxia. Aim of the present Phase I study was to firstly evaluate in non-small cell lung cancer patients the human biodistribution and dosimetry of (18)F-FAZA. Methods: Five patients awaiting surgical resection after histologically proven or radiologically suspected non-small cell lung cancer were prospectively enrolled for the study. The patients underwent a PET/computed tomography (CT) study after the injection of 371±32 MBq of (18)F-FAZA...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28207521/quantitative-assessment-of-the-relationship-between-rassf1a-gene-promoter-methylation-and-bladder-cancer-prisma
#4
Leyun Zhan, Bingyi Zhang, Yaojun Tan, Chengliang Yang, Chenhong Huang, Qiongya Wu, Yulin Zhang, Xiaobo Chen, Mi Zhou, Aihua Shu
BACKGROUND: Methylation of the Ras-association domain family 1 isoform A (RASSF1A) gene promoter region is thought to participate in the initiation and development of many different cancers. However, in bladder cancer the role of RASSF1A methylation was unclear. To evaluate the relationship between RASSF1A methylation and bladder cancer, a quantitative assessment of an independent meta-analysis was performed. In addition, a DNA methylation microarray database from the cancer genome atlas (TCGA) project was used to validate the results of the meta-analysis...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28199978/down-regulation-of-lncrna-casc2-promotes-cell-proliferation-and-metastasis-of-bladder-cancer-by-activation-of-the-wnt-%C3%AE-catenin-signaling-pathway
#5
Zhijun Pei, Xian Du, Yafeng Song, Lin Fan, Fuyan Li, Yan Gao, Ruimin Wu, Yijia Chen, Wei Li, Hong Zhou, Yi Yang, Jing Zeng
Long noncoding RNAs cancer susceptibility candidate 2 (CASC2) have been demonstrated as playing crucial regulatory roles in a few of cancers. However, the biological function of lncRNA CASC2 in bladder cancer are still unclear. In this study, we found that lncRNA CASC2 was significantly down-regulated in bladder cancer tissues and cell lines by quantitative real time-PCR and associated with advanced TNM stage (III/IV). Moreover, overexpression of lncRNA CASC2 remarkably reduced the cell growth, migration and invasion, as well as promoted early apoptosis of bladder cancer cell in vitro...
February 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28193625/deep-sequencing-of-urinary-rnas-for-bladder-cancer-molecular-diagnostics
#6
Mandy L Y Sin, Kathleen E Mach, Rahul Sinha, Fan Wu, Dharati Trivedi, Emanuela Altobelli, Kristin C Jensen, Debashis Sahoo, Ying Lu, Joseph C Liao
PURPOSE: The majority of bladder cancer patients present with localized disease and are managed by transurethral resection. However, the high rate of recurrence necessitates lifetime cystoscopic surveillance. Developing a sensitive and specific urine-based test would significantly improve bladder cancer screening, detection, and surveillance. EXPERIMENTAL DESIGN: RNA-seq was used for biomarker discovery to directly assess the gene expression profile of exfoliated urothelial cells in urine derived from bladder cancer patients (n=13) and controls (n=10)...
February 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28167242/epigenome-wide-dna-methylation-profiling-identifies-differential-methylation-biomarkers-in-high-grade-bladder-cancer
#7
Ekaterina Olkhov-Mitsel, Andrea J Savio, Ken J Kron, Vaijayanti V Pethe, Thomas Hermanns, Neil E Fleshner, Bas W van Rhijn, Theodorus H van der Kwast, Alexandre R Zlotta, Bharati Bapat
Epigenetic changes, including CpG island hypermethylation, occur frequently in bladder cancer (BC) and may be exploited for BC detection and distinction between high-grade (HG) and low-grade (LG) disease. Genome-wide methylation analysis was performed using Agilent Human CpG Island Microarrays to determine epigenetic differences between LG and HG cases. Pathway enrichment analysis and functional annotation determined that the most frequently methylated pathways in HG BC were enriched for anterior/posterior pattern specification, embryonic skeletal system development, neuron fate commitment, DNA binding, and transcription factor activity...
February 3, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28165132/nonmuscle-invasive-bladder-cancer-what-s-changing-and-what-has-changed
#8
Ramanitharan Manikandan, Oscar Rodriguez, Rubén Parada, Joan Palou Redorta
PURPOSE: Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette-Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish 'what changes has already occurred and what is expected in the future' in NMIBC...
February 3, 2017: Urologia
https://www.readbyqxmd.com/read/28164165/accuracy-of-self-reported-smoking-exposure-among-bladder-cancer-patients-undergoing-surveillance-at-a-tertiary-referral-center
#9
Alan E Thong, Stacey Petruzella, Irene Orlow, Emily C Zabor, Behfar Ehdaie, Jamie S Ostroff, Bernard H Bochner, Helena Furberg Barnes
BACKGROUND: Smoking is a risk factor for developing bladder cancer (BCa). Even though continued exposure after diagnosis may adversely affect prognosis, patients may be reluctant to disclose to their physicians that they are currently smoking, leading to inaccurate reporting of exposure and missed opportunities to deliver smoking-cessation advice and treatment in the context of cancer care. OBJECTIVE: We examined the extent of misclassification of recent smoking exposure among patients undergoing BCa surveillance...
October 2016: European Urology Focus
https://www.readbyqxmd.com/read/28163793/uromark-a-urinary-biomarker-assay-for-the-detection-of-bladder-cancer
#10
Andrew Feber, Pawan Dhami, Liqin Dong, Patricia de Winter, Wei Shen Tan, Mónica Martínez-Fernández, Dirk S Paul, Antony Hynes-Allen, Sheida Rezaee, Pratik Gurung, Simon Rodney, Ahmed Mehmood, Felipe Villacampa, Federico de la Rosa, Charles Jameson, Kar Keung Cheng, Maurice P Zeegers, Richard T Bryan, Nicholas D James, Jesus M Paramio, Alex Freeman, Stephan Beck, John D Kelly
BACKGROUND: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay to diagnose BC from urine with high sensitivity and specificity...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28157704/overlooked-fancd2-variant-encodes-a-promising-portent-tumor-suppressor-and-alternative-polyadenylation-contributes-to-its-expression
#11
Bing Hang, Yihang Shen, Piyan Zhang, Panneerselvam Jayabal, Raymond Che, Jun Zhang, Herbert Yu, Peiwen Fei
Fanconi Anemia (FA) complementation group D2 protein (FANCD2) is the center of the FA tumor suppressor pathway, which has become an important field of investigation in human aging and cancer. Here we report an overlooked central player in the FA pathway, FANCD2 variant 2 (FANCD2-V2), which appears to perform more potent tumor suppressor-function compared to the known variant of FANCD2, namely, FANCD2-V1. Detailed analysis of the FANCD2 gene structure indicated a proximal and distal polyadenylation site (PAS), associated with V2 and V1 transcripts accordingly...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28157703/discovery-and-validation-of-potential-urinary-biomarkers-for-bladder-cancer-diagnosis-using-a-pseudotargeted-gc-ms-metabolomics-method
#12
Yang Zhou, Ruixiang Song, Chong Ma, Lina Zhou, Xinyu Liu, Peiyuan Yin, Zhensheng Zhang, Yinghao Sun, Chuanliang Xu, Xin Lu, Guowang Xu
Bladder cancer (BC) is the second most prevalent malignancy in the urinary system and is associated with significant mortality; thus, there is an urgent need for novel noninvasive diagnostic biomarkers. A urinary pseudotargeted method based on gas chromatography-mass spectrometry was developed and validated for a BC metabolomics study. The method exhibited good repeatability, intraday and interday precision, linearity and metabolome coverage. A total of 76 differential metabolites were defined in the discovery sample set, 58 of which were verified using an independent validation urine set...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28156048/targeted-o-glycoproteomics-explored-increased-sialylation-and-identified-muc16-as-a-poor-prognosis-biomarker-in-advanced-stage-bladder-tumours
#13
Sofia Cotton, Rita Azevedo, Cristiana Gaiteiro, Dylan Ferreira, Luís Lima, Andreia Peixoto, Elisabete Fernandes, Manuel Neves, Diogo Neves, Teresina Amaro, Ricardo Cruz, Ana Tavares, Maria Rangel, André M N Silva, Lúcio Lara Santos, José Alexandre Ferreira
Bladder carcinogenesis and tumour progression is accompanied by profound alterations in protein glycosylation on the cell surface, which may be explored for improving disease management. In a search for prognosis biomarkers and novel therapeutic targets we have screened, using immunohistochemistry, a series of bladder tumours with differing clinicopathology for short-chain O-glycans commonly found in glycoproteins of human solid tumours. These included the Tn and T antigens and their sialylated counterparts sialyl-Tn(STn) and sialyl-T(ST), which are generally associated with poor prognosis...
February 3, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28151475/overexpression-of-slc34a2-is-an-independent-prognostic-indicator-in-bladder-cancer-and-its-depletion-suppresses-tumor-growth-via-decreasing-c-myc-expression-and-transcriptional-activity
#14
Wen Ye, Cui Chen, Ying Gao, Zou-Shan Zheng, Yi Xu, Miao Yun, Hui-Wen Weng, Dan Xie, Sheng Ye, Jia-Xing Zhang
Solute carrier family 34 member 2 (SLC34A2), a pH-sensitive sodium-dependent phosphate transporter, is associated with several human cancers. In this study, we investigate the clinical significance of SLC34A2 and its function in human bladder cancer (BC). The expression dynamics of SLC34A2 were examined in two independent cohorts of BC samples by quantitative PCR, western blotting and immunohistochemical staining. In the training cohort (156 cases), we applied the X-tile program software to assess the optimal cutoff points for biomarkers in order to accurately classify patients according to clinical outcome...
February 2, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28149930/ten-years-of-proteomics-in-bladder-cancer-progress-and-future-directions
#15
REVIEW
Maria Frantzi, Antonia Vlahou
Research efforts targeting the identification of bladder cancer biomarkers have been extensive during the past decade. Investigations have been performed at the genome, transcriptome, proteome, and metabolome levels and outputs have started appearing including the sketching of disease molecular subtypes. Proteins are directly linked to cell phenotype hence they accumulate special interest as both biomarkers and therapeutic targets. Multiple technical challenges exist, of the main, being the protein concentration vast dynamic range and presence of proteins in modified forms...
January 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28135623/molecular-biomarkers-to-predict-response-to-neoadjuvant-chemotherapy-for-bladder-cancer
#16
REVIEW
Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Giorgio V Scagliotti, Massimo Di Maio
Cystectomy is the gold standard for treatment of localized muscle-invasive bladder cancer. However, about 50% of patients develop metastases within 2years after cystectomy and subsequently die for the disease. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival in patients with muscle-invasive bladder cancer, and pathological response to neoadjuvant treatment (downstaging to ⩽pT1 at cystectomy) is a strong predictor of better disease-specific survival. Nevertheless, some patients do not benefit from neoadjuvant therapy...
January 11, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28132875/the-impact-of-cruciferous-vegetable-isothiocyanates-on-histone-acetylation-and-histone-phosphorylation-in-bladder-cancer
#17
Besma Abbaoui, Kelly H Telu, Christopher R Lucas, Jennifer M Thomas-Ahner, Steven J Schwartz, Steven K Clinton, Michael A Freitas, Amir Mortazavi
: Cruciferous vegetable intake is associated with reduced risk of bladder cancer, yet mechanisms remain unclear. Cruciferous vegetable isothiocyanates (ITCs), namely sulforaphane (SFN) and erucin (ECN), significantly inhibit histone deacetylase (HDAC) activity in human bladder cancer cells representing superficial to invasive biology (59-83% inhibition with 20μM, 48h treatment), and in bladder cancer xenografts (59±3% ECN inhibition). Individual HDACs inhibited by SFN and ECN include HDACs 1, 2, 4 and 6...
March 6, 2017: Journal of Proteomics
https://www.readbyqxmd.com/read/28132182/applications-of-metabolomics-in-cancer-studies
#18
Emily Grace Armitage, Michal Ciborowski
Since the start of metabolomics as a field of research, the number of studies related to cancer has grown to such an extent that cancer metabolomics now represents its own discipline. In this chapter, the applications of metabolomics in cancer studies are explored. Different approaches and analytical platforms can be employed for the analysis of samples depending on the goal of the study and the aspects of the cancer metabolome being investigated. Analyses have concerned a range of cancers including lung, colorectal, bladder, breast, gastric, oesophageal and thyroid, amongst others...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28127179/molecular-and-functional-diagnostic-tools-in-precision-oncology-for-urological-malignancies
#19
REVIEW
Vasanthakumar Sekar, Debapriya Ghosh Mehrotra, Biswanath Majumder
Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting...
March 2017: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28123579/mir-143-inhibits-bladder-cancer-cell-proliferation-and-enhances-their-sensitivity-to-gemcitabine-by-repressing-igf-1r-signaling
#20
Hengbing Wang, Qi Li, Xiaobing Niu, Gongcheng Wang, Sinian Zheng, Guangbo Fu, Zengjun Wang
microRNAs (miRNAs) are a class of small RNAs that regulate gene expression. It has been demonstrated that aberrant miRNA expression is associated with cancer development and carcinogenesis. Altered miRNA expression has been suggested to occur in bladder cancer. In other cancer systems, studies have indicated that miR-143, as a tumor suppressor gene, plays essential roles in cancer progression. However, its role in bladder cancer has yet to be elucidated. In the present study, we observed that miR-143 expression was downregulated in human bladder cancer tissues and cells, and that its levels were negatively correlated with bladder cancer clinical stages...
January 2017: Oncology Letters
keyword
keyword
91964
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"